1. Clinical & Scientific Overview
Ramipril (TIP-MED-000005, Reference Code [3.5]) is classified under
Cardiovascular & Antithrombotic Medicines (Ch 03) as a Angiotensin-Converting Enzyme (ACE) Inhibitor (Prodrug converted to Ramiprilat).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Cardace (Sanofi), Ramistar (Lupin), Ramipres (Cipla), Hopace (Micro Labs)
Oral Capsules / Tablets: 1.25 mg, 2.5 mg, 5 mg, 10 mg
3. Mechanism of Action & Pharmacodynamics
Angiotensin-Converting Enzyme (ACE) Inhibitor (Prodrug converted to Ramiprilat) acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Angiotensin-Converting Enzyme (ACE) Inhibitor (Prodrug converted to Ramiprilat) for Hypertension; heart failure with reduced ejection fraction (HFrEF) and post-myocardial infarction LV dysfunction; diabetic and non-diabetic proteinuric nephropathy; secondary cardiovascular prevention in high-risk patients..
4. Therapeutic Indications & Evidence-Supported Uses
- Hypertension
- heart failure with reduced ejection fraction (HFrEF) and post-myocardial infarction LV dysfunction
- diabetic and non-diabetic proteinuric nephropathy
- secondary cardiovascular prevention in high-risk patients
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Hypertension: Initially 2.5 mg OD, maintenance 2.5–10 mg/day (as OD or divided BD). Heart Failure / Post-MI: Initially 1.25 mg–2.5 mg OD/BD, titrated slowly to target 5 mg BD or 10 mg OD as tolerated. Follow physician titration.
Administration & Meal Timing: May be taken before, during, or after meals (food delays absorption rate slightly but does not reduce total bioavailability of ramiprilat). | Initial first dose preferably at bedtime (to prevent first-dose orthostatic syncope); subsequent maintenance doses in the morning or divided morning and evening.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Explicitly renal-function dependent! Ramiprilat is renally cleared: if CrCl 20–50 mL/min, initiate at 1.25 mg OD (max 5 mg/day); if CrCl <20 mL/min, initiate at 1.25 mg OD and do not exceed 2.5 mg/day. Acceptable creatinine rise up to 20–30% after initiation stabilises intraglomerular pressure; if >30% rise, withhold and evaluate for renal artery stenosis. Hepatic: Impaired esterase conversion to ramiprilat; initiate at 1.25 mg OD under close monitoring (max 2.5 mg/day).
Renal: Explicitly renal-function dependent! Ramiprilat is renally cleared: if CrCl 20–50 mL/min, initiate at 1.25 mg OD (max 5 mg/day); if CrCl <20 mL/min, initiate at 1.25 mg OD and do not exceed 2.5 mg/day. Acceptable creatinine rise up to 20–30% after initiation stabilises intraglomerular pressure; if >30% rise, withhold and evaluate for renal artery stenosis. Hepatic: Impaired esterase conversion to ramiprilat; initiate at 1.25 mg OD under close monitoring (max 2.5 mg/day).
Renal: Explicitly renal-function dependent! Ramiprilat is renally cleared: if CrCl 20–50 mL/min, initiate at 1.25 mg OD (max 5 mg/day); if CrCl <20 mL/min, initiate at 1.25 mg OD and do not exceed 2.5 mg/day. Acceptable creatinine rise up to 20–30% after initiation stabilises intraglomerular pressure; if >30% rise, withhold and evaluate for renal artery stenosis. Hepatic: Impaired esterase conversion to ramiprilat; initiate at 1.25 mg OD under close monitoring (max 2.5 mg/day).
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in pregnancy, history of ACE-inhibitor-induced or hereditary angioedema, bilateral renal artery stenosis, and within 36 hours of switching to/from Sacubitril/Valsartan (ARNI). Avoid combination with ARBs.
Key Clinical Precautions: Renal: Explicitly renal-function dependent! Ramiprilat is renally cleared: if CrCl 20–50 mL/min, initiate at 1.25 mg OD (max 5 mg/day); if CrCl <20 mL/min, initiate at 1.25 mg OD and do not exceed 2.5 mg/day. Acceptable creatinine rise up to 20–30% after initiation stabilises intraglomerular pressure; if >30% rise, withhold and evaluate for renal artery stenosis. Hepatic: Impaired esterase conversion to ramiprilat; initiate at 1.25 mg OD under close monitoring (max 2.5 mg/day).
8. Adverse Effects Profile
- Persistent dry, non-productive hacking cough (5–20% of Indian patients, due to bradykinin and substance P accumulation), dizziness, postural lightheadedness, fatigue, metallic taste.
- Life-threatening angioedema (swelling of lips, tongue, pharynx, larynx—medical emergency), severe hyperkalaemia (K+ >5.5 mEq/L), acute renal failure, rare neutropenia/agranulocytosis.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Sacubitril/valsartan within 36 hours (severe angioedema risk)
- Co-administration with mTOR inhibitors or DPP-4 inhibitors (vildagliptin/sitagliptin) slightly increases angioedema risk
- Potassium-sparing diuretics, K+ supplements, and cotrimoxazole (trimethoprim) cause severe hyperkalaemia
- NSAIDs blunt BP control and precipitate acute kidney injury
- Increases lithium levels
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Take the very first tablet while seated or at bedtime to avoid dizziness. Explain that a dry, tickly throat cough that does not respond to cough syrups is a known side effect—if it disturbs sleep, the doctor can easily switch it to an ARB (like telmisartan). Seek emergency care immediately if lip or tongue swelling occurs.
- Meal & Clock Timing Instruction: May be taken before, during, or after meals (food delays absorption rate slightly but does not reduce total bioavailability of ramiprilat). (Initial first dose preferably at bedtime (to prevent first-dose orthostatic syncope); subsequent maintenance doses in the morning or divided morning and evening.)
- Missed Dose Protocol: Take on the same calendar day if remembered earlier in the day; if close to the next scheduled dose, skip the missed dose and resume the regular schedule. Never double the dose.
- Geriatric Dispensing Pearl: Start at 1.25 mg once daily in elderly patients, especially those on furosemide/torsemide or with heart failure. Always enforce the 'Sick Day Rule': temporarily pause ramipril during acute gastroenteritis, vomiting, or severe fever with dehydration to prevent acute kidney injury.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Capsules / Tablets: 1.25 mg, 2.5 mg, 5 mg, 10 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.5] (p. 23)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.